Forum You Cannot Have Your Synergy and Efficacy Too Pramita Sen, 1, 3, 4 Ananya Saha, 1, 4 and Narendra M. Dixit 1,2, * Synergistic drugs are preferred in combination therapies for many diseases, including viral infections and cancers. Maximizing synergy, however, may come at the cost of efficacy. This synergy-efficacy trade-off appears to be widely prevalent and independent of the specific drug interactions yielding synergy. We present examples of the trade-off in drug combinations used in hepatitis C, HIV, and cancer therapies and believe that screens for optimal drug combinations that presently seek to maximize synergy may be improved by considering the trade-off.
Synergistic Drug Combinations
Drug combinations form the mainstay of current therapies for cancers, infectious diseases, and lifestyle disorders [1] . They have two significant advantages over therapies involving single drugs [1] : first, by attacking multiple targets, they may reduce the chances of drug resistance; and, second, because the drugs can each be used at lower dosages in combination than if used alone, they may cause less severe side-effects. Here, drugs that exhibit synergistic interactions are particularly beneficial. Broadly, synergistic interactions result in the drug combination having an effect that is larger than the independent effects of the individual drugs combined [1] [2] [3] . Consequently, synergistic drug combinations can achieve the desired efficacies at much lower dosages, further reducing sideeffects and costs. Alternatively, they may allow greater efficacies at tolerable toxicities [4] . Significant efforts are invested therefore in identifying synergistic drug combinations. For example, every pair of 19 anti-HIV drugs [5] and numerous two-and three-drug combinations for hepatitis C virus (HCV) infection [6] have been assessed to identify the most synergistic combinations.
Recognizing the wider importance of such screening, algorithms and automated platforms, including those using modern deep learning techniques, have been proposed for the identification of synergistic drug combinations [3, 7, 8] .
Sounding a cautionary note, we argue here that this quest for synergy, while desirable, cannot be unconstrained. Beyond a limit, synergy may come at the cost of efficacy. Evidence of this trade-off between synergy and efficacy 
Examples of the Synergy-Efficacy Trade-Off
We trace the earliest evidence of the synergy-efficacy trade-off to studies nearly 15 years ago on the combination of interferon and ribavirin (Table 1) , which was then the standard of care for chronic HCV infection [9] . Ribavirin alone was found not to cure HCV infection. Interferon monotherapy yielded cure rates of $20% [9] . Combining interferon with ribavirin improved cure rates dramatically to $62% on average [9] . The drugs thus acted synergistically. The extent of synergy, however, was reduced when interferon was more potent and resulted in higher cure rates by itself. The pegylated form of interferon, for instance, elicited cure rates of $45% alone, compared with $20% by its nonpegylated form, indicating greater interferon efficacy in the pegylated form [9] . Combining ribavirin with pegylated interferon increased the cure rate to $76%, a much smaller increase than above, implying reduced synergy with increased efficacy [9] , indicative of the synergy-efficacy trade-off.
Formally, let ε 1 and ε 2 be the efficacies of drug 1 and drug 2, respectively, and let ε comb be their combined efficacy. If the drugs were to act independently, ε comb would be equal to ε B given by the Bliss independence formula:
. When ε comb is higher than ε B , the combination exhibits Bliss synergy, quantified as b B = ε comb À ε B (Box 1). Thus, higher b B implies higher synergy. If we define efficacy as cure rate, it follows that b B decreases as ε comb increases (Table 1) , quantifying the synergy-efficacy tradeoff in the interferon-ribavirin combination discussed above.
Chronic HCV infection is treated today with combinations of direct-acting antiviral agents (DAAs), which target different steps of the HCV lifecycle. DAA combinations also present evidence of the trade-off (Table 1) . Xiao et al. examined the effect of inhibitors of HCV entry into cells when combined with other drugs [10] . They quantified synergy using the combination index,
ε , where (D 1 ) ε and (D 2 ) ε are the concentrations (or dosages) of drugs 1 and 2 that individually yield efficacy ε, typically following the medianeffect equation (see Equation I in Box 1), and D 1 and D 2 are their concentrations that yield the same efficacy in combination. CI < 1 implies synergy between the drugs; the smaller the CI, the greater the extent of the synergy. Xiao et al. found that CI often increased with ε [10] . For instance, with the drugs boceprevir and erlotinib CI increased from 0.25 to 0.75 as ε increased from 0.5 to 0.9, where ε is defined as the fraction of infection events prevented by the drug(s). Thus, synergy decreased as efficacy increased. This trend was seen with several DAA combinations and with many DAAs in combination with monoclonal antibodies blocking HCV entry (Table 1 ) [10] .
Some current antiretroviral drugs for HIV treatment also exhibit the tradeoff ( Table 1 ). Jilek et al. [5] quantified antiretroviral drug action using f u , the fraction of infection events unaffected by the drug(s). The efficacy of the drug(s) is thus ε = 1 À f u . From the data reported in Jilek et al. [5] , we found that for the drugs nevirapine and zidovudine, which interacted synergistically, as the concentrations decreased from the maximum levels studied, the efficacy (ε) decreased but Bliss synergy increased ( Table 1 ). The same trend was observed for the drugs dolutegravir and tenofovir [11] (Table  1 ). The synergy-efficacy trade-off is thus evident in these drug combinations. More recently, stochastic simulations of the effect of HIV latencyreversing agents too have argued that increasing Bliss synergy beyond a point compromises efficacy [12] .
Finally, we present evidence of the trade-off in anticancer drugs. In a recent study, several chondrosarcoma cell lines resistant to chemotherapy were made sensitive to cisplatin by inhibiting the antiapoptotic protein Bcl-xl using the drug WEHI-539 [13] . Experiments used a fixed level of WEHI-539 and different levels of cisplatin, ranging from 0.39 to 100 mM. The level of Bliss synergy (b B ) was estimated as defined in Box 1. With several cell lines where synergy was observed, the maximum synergy occurred at intermediate drug, and therefore efficacy, levels (Table 1). For instance, b B was highest at 12.5 mM cisplatin for the cell line SW1353 and at 6.25 mM cisplatin for the cell line L835 [13] (Table 1) . Increasing the cisplatin level beyond this value increased efficacy but compromised synergy, reflecting the synergy-efficacy trade-off. In another study on adult T cell leukemia cell lines, ruxolitinib, an inhibitor of Janus kinase (JAK), was examined for its activity in combination with each of >450 potential drugs using high-throughput matrix screens [14] . The response in terms of cell viability relative to that in the absence of treatment was measured.
For several drug combinations, as the combined efficacy (ε), defined as the decrease in cell viability, increased, Bliss synergy decreased. For instance, for the combination of ruxolitinib and panobinostat, as ε increased from 0.89 to 0.96, b B decreased from 0.14 to 0.08 (Table 1) . Similarly, for the combination of ruxolitinib and withaferin A, a gain in ε from 0.32 to 0.47 was associated with a loss in b B from 0.22 to 0.12 (Table 1) . Thus, examples abound of the synergy-efficacy trade-off across diseases and drug combinations.
Origin of the Synergy-Efficacy Trade-Off
The numerous examples above of the synergy-efficacy trade-off, across diseases and drug combinations, suggest that the trade-off is an inherent characteristic of synergistic drug combinations and is independent of the specific mechanisms of the drug interactions yielding synergy. In accordance, we show that a generalized, mechanismagnostic model of drug interactions recapitulates the synergy-efficacy tradeoff (Box 1). While efficacy increases monotonically with drug levels, synergy first rises and then falls (see Figure I in Box 1). These trends can be understood as follows. When the drugs are at low concentrations, minimal interactions are expected to occur between the Trends in Pharmacological Sciences, November 2019, Vol. 40, No. 11 813
Box 1. A Generalized Model of Drug Interactions Predicts the Synergy-Efficacy Trade-Off
Consider drugs 1 and 2, used at dosages D 1 and D 2 , acting with efficacies ε 1 and ε 2 , respectively. Let their dose-response relationships follow the median-effect equation [2, 5] ,
where: ε i max (i = 1, 2) represents the maximum efficacy of drug i, attained at large values of D i ; IC 50 i , the potency of drug i, represents the value of D i at which ε i = 0.5ε i max ; and m i , the slope parameter, defines the steepness of the dose-response curve near D i = IC 50 i . We let the drugs exhibit synergistic interactions. Thus, we write the combined efficacy of the drugs as
Here, IC 12 50 = IC 1 50 = 1 + g 12 Equation II has a structure similar to the generalized 2D Hill equation derived recently to quantify drug interactions [3] and reduces to expected forms under several limiting scenarios. When a single drug is used, ε comb reduces to the single-drug efficacy; that is, ε comb = ε 1 when D 2 = 0. When a = g 12 = g 21 = 0, indicating no interactions, Bliss independence results: ε comb = ε B = ε 1 + ε 2 À ε 1 ε 2 . With a > 0 and g 12 = g 21 = 0, the drugs exhibit synergy in efficacy. When g 12 > 0 or g 21 > 0 or both, but a = 0, the drugs exhibit synergy in potency. (When any of the latter constants become negative, the drugs exhibit antagonistic interactions, not considered here.)
We quantified synergy using both Bliss synergy, b B = ε comb À ε B , and Loewe synergy, b L = ε comb À ε L , where the efficacy due to Loewe additivity, ε L , is obtained by solving [2, 19] 
We varied D 1 and D 2 and computed the efficacy, ε comb , and the extent of synergy, b B and b L , using the expressions above for parameters representing synergy in efficacy or potency ( Figure IA,B ). As expected, ε comb increased with D 1 and D 2 . Both b B and b L , however, varied nonmonotonically with D 1 and D 2 , rising from low values initially, attaining a peak, and then decreasing as ε comb approached its maximum. The latter decrease in b with increase in ε comb reflects the synergy-efficacy trade-off.
We found that, with sufficient data, the model could fit experimental measurements of ε comb versus D 1 and D 2 well and with the resulting best-fit parameter estimates capture the observed synergy-efficacy trade-off ( Figure IC) .
We can explain the trends leading up to the synergy-efficacy trade-off analytically under certain conditions. For synergy in efficacy (a > 0;g 12 = g 21 = 0), combining Equations I and II yields
Thus, b B is small when ε 1 and ε 2 are small, reflecting dosages too low for significant interactions between the individual drug effects. As ε 1 and ε 2 rise, interactions become significant and b B rises. When ε 1 and ε 2 approach their respective maximum values, so does ε B , driving b B to zero regardless of a.
Similarly, for synergy in potency, where drug 1 potentiates drug 2 (a = 0;g 12 = 0;g 21 > 0), we can show, when m 1 = m 2 = 1, that
which also show ε comb increasing to ε B max and b B decreasing to zero when ε 1 and ε 2 approach their respective maxima. For [14] are in symbols and model fits and predictions are in lines. Fits were obtained by first considering single-drug data (left inset), which yielded m 1 = 0.70 G 0.15, IC 50 1 = 93 G 25 nM, m 2 = 1.9 G 0.5, and IC 50 2 = 12 G 2 nM. The observed efficacies at high concentrations suggested ε 1 max = ε 2 max = 1, which we fixed. With these parameters, we then fit the efficacy data of the combination at all of the dosages employed, which Beyond a point, however, efficacy continues to rise with drug levels but synergy drops. Synergy requires that an effect beyond the independent effects of drugs appears. When a drug is used at a high dosage, its independent effect can elicit near-maximal efficacy, such as maximal blocking of a target receptor or maximal excitation of a downstream pathway, leaving little room for the other drug to improve its activity. The scope for synergy thus shrinks, explaining the trade-off. This general explanation of the trade-off is also borne out in specific cases where the mechanisms of drug interactions are explicitly incorporated in detailed mathematical models, as with interferon and ribavirin [9] and HIV latencyreversing agents [12] .
Concluding Remarks
Drug levels that maximize synergy need not simultaneously maximize efficacy. While synergy is desirable, it cannot come at the cost of efficacy. We found evidence of the synergy-efficacy trade-off from studies that examined drug interactions over concentration ranges wide enough to realize the trade-off. The search for maximum synergy must therefore be constrained by the desired efficacy, especially when side-effects are manageable. Such con-strained optimization has been proposed earlier for HIV latency-reversing agents [12] . Because the trade-off is independent of the specific mechanisms underlying synergy, future studies may seek it in drug combinations beyond our study.
Often, a critical level of efficacy to achieve the desired therapeutic effect can be estimated from independent considerations. For instance, a critical efficacy can be defined based on the within-host basic reproductive ratio of viruses, a quantitative measure of virulence, to elicit adequate control of viral infections using antiviral therapies [15] . If the critical efficacy is such that high synergy is possible without compromising efficacy, optimal combinations may benefit from incorporating synergistic drugs. If the critical efficacy is high enough that little room for synergy is left, screening for optimal drug combinations need not prefer synergistic drugs.
It is important to note that drugs acting independently may appear synergistic at the population level because different individuals may respond differently to the drugs in a combination [16] . Different cells in an individual can also respond differently to different drugs [17] . Our arguments of the tradeoff apply to drugs manifesting intrinsic synergistic interactions. Finally, we recognize that synergistic drug combinations may accelerate the evolution of multidrug resistance, and conditions that preclude such evolution are screened for in optimizing treatments [18] . Future efforts to optimize drug combinations would similarly benefit from accounting for the synergyefficacy trade-off.
